Global Ovarian Cancer Market

Description

Market Overview

Ovarian Cancer Market was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 16% during the forecast period (2022-2029).

Ovarian cancer is the deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.

Market Dynamics

The major driving forces are rising ovarian cancer incidence, a growing number of clinical trials for innovations, increasing health expenditure, the use of combination therapies to treat ovarian cancer, and an increasing geriatric population.

The increasing burden of ovarian cancer and the growing female geriatric population drive global market growth.

The growing prevalence and female geriatric population are fueling the global market growth. For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall. As per the NIH, there were more than 313,000 new cases of ovarian cancer in 2020, and a total of 207,252 new deaths from ovarian cancer were reported globally; ovarian carcinoma is the most common type of ovarian cancer, comprising over 90% of all ovarian cancer cases. Furthermore, according to the NIH, the risk of ovarian cancer increases in females with age; therefore, the growing female geriatric population drives the global market growth. For instance, 727 million persons aged 65 years or over in 2020. Since women live longer than men, they comprise the majority of older persons, especially at advanced ages.

The costly cancer treatment is restraining the global Ovarian Cancer growth.

However, the high cost of cancer treatment, lack of accurate diagnosis of ovarian cancer, and lack of awareness in emerging and low-income economies are expected to restrain the market. For patients without health insurance, the cost ranges from $20,000 to $200,000 or more for treatment with surgery and chemotherapy for advanced cancer.

Global Ovarian Cancer Market-Industry analysis.

The global ovarian cancer report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, pipeline analysis Etc.

Segment Analysis

The imaging test market is expected to have a greater grasp of the Ovarian Cancer market during the forecast period (2022-2029)

Epithelial ovarian cancer dominated the global market in 2021. It is expected to show a similar trend throughout the forecast period (2022-2029), as epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are a phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, a phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early relapse (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more.

Geographical Analysis

The Asia Pacific is expected to command dominating the global ovarian cancer market.

The Asia Pacific is predicted to command the global ovarian cancer market since the Asia Pacific has the highest prevalence of ovarian cancer and the largest portion of the global population. For instance, according to the statistics from the WHO, in 2020, Eastern Asia had 71 353 new cases and 45 690 deaths due to ovarian cancer, South-Eastern Asia had 31 169 new cases and 20 012 deaths because of ovarian cancer, South-Central Asia had 59 730 new cases and 41 407 deaths of ovarian cancer patients while Western Asia had 8 507 new cases and 5 827 deaths as a result of ovarian cancer advancement. Furthermore, the Asia Pacific has the highest populated countries in the world, India and China; for instance, in 2021, India's population was 1.412 billion, compared to China's 1.426 billion. The Asia Pacific accounts for 60% of the global population, fueling the ovarian cancer market growth in this region.

Competitive Landscape

The key players operating in the global ovarian cancer market are Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the ovarian cancer market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

AstraZeneca plc

Overview:

AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK.

Product Portfolio:

The product portfolio of AstraZeneca plc for ovarian cancer has LYNPARZA.

The global ovarian cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Product Code: DMPH2179

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The Increasing Burden of Ovarian Cancer
  - 4.1.1.2. Rising Female Geriatric Population
- 4.1.2. Restraints
  - 4.1.2.1. High Cost
  - 4.1.2.2. Lack of Treatment Options
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer's Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
- 7.1.2. Market Attractiveness Index, By Type Segment
7.2. Epithelial Ovarian Cancer
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Germ Cell Ovarian Cancer
7.4. Stromal Cell Ovarian Cancer
7.5. Small Cell Ovarian Cancer

8. By Treatment Type

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
- 8.1.2. Market Attractiveness Index, By Treatment Type Segment
8.2. Targeted Therapy
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Surgery
8.4. Chemotherapy
8.5. Immunotherapy
8.6. Others

9. By Diagnosis Type

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type Segment
- 9.1.2. Market Attractiveness Index, By Diagnosis Type Segment
9.2. Blood Tests
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Imaging Tests
9.4. Laparoscopy
9.5. Colonoscopy
9.6. Others

10. By Drug class

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
- 10.1.2. Market Attractiveness Index, By Drug Class Segment
10.2. PARP Inhibitors
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Angiogenesis Inhibitors
10.4. PD-L1 Inhibitors

11. By End User

11.1. Introduction
- 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
- 11.1.2. Market Attractiveness Index, By End User Segment
11.2. Hospitals And Clinics
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
11.3. Diagnostic Centers
11.4. Cancer Research Centers
11.5. Other

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. The U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. The U.K.
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. China
  - 12.5.8.2. India
  - 12.5.8.3. Japan
  - 12.5.8.4. Australia
  - 12.5.8.5. Rest of Asia Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
- 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
- 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
- 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

13.1. Key Developments and Strategies
13.2. Company Share Analysis
13.3. Product Benchmarking

14. Company Profiles

14.1. AstraZeneca
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Key Highlights
- 14.1.4. Financial Overview
14.2. Roche
14.3. GlaxoSmithKline
14.4. Boehringer Ingelheim
14.5. Bristol-Myers Squibb
14.6. Novartis
14.7. Celgene
14.8. Amgen
14.9. Pfizer
14.10. Merck

LIST NOT EXHAUSTIVE

15. DataM

15.1. Appendix
15.2. About Us and Services
15.3. Contact Us

Global Ovarian Cancer Market - 2022-2029